Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ABEOCLEVELAND, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new executive and non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
ABEOCLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ABEO(NASDAQ:ABEO) CLEVELAND, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
ABEO(NASDAQ:ABEO) CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2025:
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
ABEO- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19
ABEOWhy E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
ABEOStifel Maintains Buy on Abeona Therapeutics, Lowers Price Target to $20
ABEOAbeona Therapeutics Q1 EPS $(0.24) Beats $(0.36) Estimate
ABEOAbeona Therapeutics And Lurie Children's Open Center For ZEVASKYNTM Gene Therapy To Treat Wounds Associated With Recessive Dystrophic Epidermolysis Bullosa
ABEOAbeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
ABEOAbeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Abeona Stock Surges to 52-Week High: What's Behind The Move?
ABEOAbeona shares are trading higher on Wednesday on possible continued strength after the FDA announced approval for its gene therapy.
12 Health Care Stocks Moving In Wednesday's Intraday Session
ABEOHC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Raises Price Target to $20
ABEOAbeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy
ABEOFDA approves Zevaskyn as the first cell-based gene therapy for RDEB wounds after strong results in pivotal and long-term studies.
The FDA Approves Abeona Therapeutics' Zevaskyn (Prademagene Zamikeracel) Gene-modified Cellular Sheets, Also Known As Pz-cel, As The First And Only Autologous Cell-based Gene Therapy For Wounds In Adult And Pediatric Patients With Recessive Dystrophic Epi
ABEOHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
ABEOAbeona Therapeutics 2024 EPS $(1.55) Up From $(2.53) YoY
ABEOThis Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
ABEOOppenheimer Initiates Coverage On Abeona Therapeutics with Outperform Rating, Announces Price Target of $16
ABEOHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
ABEOAbeona Therapeutics Q3 2024 GAAP EPS $(0.63) Misses $(0.40) Estimate
ABEOHC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
ABEOCantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21
ABEO12 Health Care Stocks Moving In Wednesday's Pre-Market Session
ABEOAbeona Therapeutics Announces AAV204, A Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration In Non-Human Primates
ABEOAbeona Therapeutics Highlights Presentation Of Data On Its Novel Capsid Candidate At Association For Research In Vision, Ophthalmology Meeting May 3 At 5:30-7:30 p.m. EDT
ABEO